STAT+: Corbus reports first Western data for closely tracked ADC cancer drug
Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.
Corbus Pharmaceuticals on Friday presented new data from the first Western study of its antibody-drug conjugate treatment for cancer that largely mirrored previous results reported from China.
In a study conducted in the U.S. and the U.K., the Corbus drug, called CRB-701, showed an overall response rate of 27% from 26 evaluable patients with nine different types of cancer — all in advanced stages.
A CRB-701 study from China presented last June showed a 28% tumor response rate from 25 evaluable patients with fewer types of cancer.
